finanzen.net
24.04.2019 12:52
Bewerten
(0)

Medtech Stock Skids On Its 'Off-Color Performance' Following FDA Jabs

DRUCKEN
Boston Scientific stock crumbled Wednesday after the medical technology company posted a "rare, off-color performance" featuring lagging revenue and earnings, and lowered expectations going forward.XMeanwhile, shares of Thermo Fisher Scientific (TMO) dipped a fraction despite a solid first quarter. Thermo Fisher earnings and sales beat expectations, and the medical technology company raised its 2019 outlook.On the stock market today, Boston Scientific stock tumbled 1.3% to close at 35.44. Thermo Fisher stock slid 0.9% to close at 261.56. Shares of medical technology companies have been under pressure recently after a "Medicare-for-All" proposal from Democratic presidential candidate Sen. Bernie Sanders.Boston Scientific Earnings, Sales Lag EstimatesFor the first quarter ended March 31, Boston Scientific adjusted earnings of 35 cents per share rose 6.1% vs. the year-earlier period. But earnings lagged estimates from analysts polled by Zacks Investment Research by a penny.Sales rose 6.3% organically to $2.49 billion, but that missed predictions for $2.54 billion.The first-quarter report was key for Boston Scientific stock. Over the last month, the Food and Drug Administration told Boston Scientific and Danish company Coloplast to stop selling a medical device used to repair pelvic organ prolapse in women due to safety issues.Further, the FDA is also questioning the safety of medical devices coated in a drug called paclitaxel. A slew of medical technology companies including Boston Scientific, SurModics (SRDX), Medtronic (MDT) and Becton Dickinson (BDX) sell these devices to treat cardiovascular conditions.But what surprised Wall Street about Boston Scientific earnings was that revenue "came in light across the board," Evercore analyst Vijay Kumar said in a note to clients. The biggest miss came from cardiovascular sales, which were 2% below expectations at $972 million. Those sales grew 6.8% organically.RBC Capital Markets analyst Brandon Henry noted neuromodulation sales growth slowed more than expected. These devices from Boston Scientific, Medtronic and Abbott Laboratories (ABT) emit electrical signals to mask pain. In the quarter, $186 million in neuromodulation sales grew 12.4% organically.Boston Scientific Stock Suffers On Guidance CutThe medical technology company narrowed its guidance for 2019. On an adjusted basis, Boston Scientific earnings are expected to come in at $1.54-$1.58 per share. Previously, the company guided to earnings of $1.53-$1.58 a share. Analysts had called for $1.56 per share.Boston Scientific also guided to 7%-8% organic growth for the year vs. its prior outlook for 7.5%-8%. That would put sales around $10.5 billion to $10.6 billion for the full year, RBC's Henry said. Analysts projected $10.63 billion in sales. Henry noted the sales guidance was in line with his own estimates.For the second quarter, the medical technology company guided to 6%-7% organic revenue growth. Boston Scientific earnings are expected to be 37-39 cents per share, a penny lower than analysts polled by Zacks at the midpoint.What could help Boston Scientific, however, is FDA approval of the medical technology company's transcatheter heart-valve replacement system, Lotus Edge, for patients with severe aortic stenosis unable to undergo surgery. Boston Scientific grabbed that long-awaited approval late Tuesday.The Lotus Edge will rival TAVR systems from Medtronic and Edwards Lifesciences (EW). Late Tuesday, Edwards said its first-quarter TAVR sales grew 8%, or 10% on an underlying basis. That lagged the global procedure growth rate "due to a modest year-over-year share decline."Thermo Fisher Earnings, Sales Top EstimatesFresh off Waters Corporation's (WAT) earnings disappointment, Thermo Fisher earnings confirmed strength in the life science tools market, Evercore analyst Ross Muken said in his report to clients. Thermo Fisher earnings and sales beat estimates, and the medical technology company raised its 2019 outlook."Thermo Fisher's first-quarter beat and raise confirms our view that the tools end market remains healthy and they are still as dominant as ever," he said. "Core growth came in at 7%, which is below the second half of 2018 levels (as expected), but impressive given the comparable quarter was 300 basis points tougher."During the first quarter, Thermo Fisher earnings of $2.81 per share, on an adjusted basis, advanced 12% to top the average estimate of analysts polled by Zacks for $2.74. Sales for the quarter ended March 30, rose 4.6% to $6.13 billion, beating expectations for $6.02 billion.The medical technology company also raised its outlook for 2019. Thermo Fisher earnings are expected to be $12.08-$12.22 per share, vs. its prior estimate for $12-$12.20 a share. That outlook for Thermo Fisher earnings was a penny below the consensus at the midpoint.Thermo Fisher also sees $25.17 billion to $25.47 billion in full-year sales, up from its previous outlook for $24.88 billion to $25.28 billion. That would account for 3%-5% growth over 2018, the medical technology company said. Analysts estimated $25.21 billion in full-year revenue.Follow Allison Gatlin on Twitter at @IBD_AGatlin.YOU MIGHT ALSO LIKE:This Medical Supplier Toppled Below A Breakout On Its Earnings LagWhy This Migraine-Focused Biotech Stock Could Be The Next TakeoverMarketSmith: Research, Charts, Data And Coaching All In One PlaceWant More IBD Insights? Subscribe To Our Investing Podcast!IBD Stock Of The Day: See How To Find, Track And Buy These Best StocksThe post Medtech Stock Skids On Its 'Off-Color Performance' Following FDA Jabs appeared first on Investor's Business Daily.
Weiter zum vollständigen Artikel bei "Investors Business Daily"
Quelle: Investors Business Daily

Nachrichten zu Boston Scientific Corp.

  • Relevant
  • Alle
    2
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Boston Scientific Corp.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
05.01.2018Boston Scientific Top PickRBC Capital Markets
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
05.01.2018Boston Scientific Top PickRBC Capital Markets
28.04.2016Boston Scientific NeutralWedbush Morgan Securities Inc.
04.05.2015Boston Scientific HoldDeutsche Bank AG
05.02.2015Boston Scientific HoldDeutsche Bank AG
30.09.2014Boston Scientific HoldNeedham & Company, LLC
07.01.2013Boston Scientific haltenDeutsche Bank Securities
13.04.2010Boston Scientific "sell"Goldman Sachs Group Inc.
17.03.2010Boston Scientific DowngradeGoldman Sachs Group Inc.
10.10.2008Boston Scientific below averageCaris & Company, Inc.
02.10.2008Boston Scientific DowngradeMerrill Lynch & Co., Inc.
13.12.2007Boston Scientific underperformFriedman, Billings Ramsey & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Boston Scientific Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX im Minus -- Asiens Börsen uneinheitlich -- Siltronic-Gewinnwarnung: Jahresziele erneut gekappt -- Vapiano rechnet auch 2019 mit Verlust -- Infineon, Immowerte im Fokus

VW will Softwareentwicklung bündeln und ausbauen. Alibaba stellt sich vor erwartetem Börsengang in Hongkong neu auf. Nordex erhält Auftrag für Projekt in den USA. Proteste erwartet: Deutsche Wohnen lädt zur Hauptversammlung. Facebook-Aktie klettert: Anleger schwelgen in Krypto-Euphorie.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
mehr Top Rankings

Umfrage

Glauben Sie die Anschuldigung der USA, dass der Iran für die Angriffe gegen Tanker im Golf von Oman verantwortlich ist?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Konjunktur/Wirtschaft
09:57 Uhr
TRADING DAY 2019 am 21.06.2019
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Lufthansa AG823212
NEL ASAA0B733
Deutsche Bank AG514000
Beyond MeatA2N7XQ
Infineon AG623100
TeslaA1CX3T
Daimler AG710000
Amazon906866
BASFBASF11
Microsoft Corp.870747
BayerBAY001
Apple Inc.865985
SteinhoffA14XB9
CommerzbankCBK100